Literature DB >> 389813

Double-blind comparison of sulphonamide-trimethoprim combinations in acute uncomplicated urinary tract infections.

O Skjerven, T Bergan.   

Abstract

The effects of a twice daily dosage of a combination of 410 mg sulphadiazine + 90 mg trimethoprim (SD + TMP) and 800 mg sulphamethoxazole + 160 mg trimethoprim (SMZ + TMP) were compared in uncomplicated urinary tract infections. All but one patient in each treatment group, i.e. 36 SD + TMP treated and 42 SMZ + TMP treated patients respectively, were cured. The percentage of side-effects related to therapy in the patients receiving the combination with sulphadiazine was 15.1% and in those with sulphamethoxazole 23.7%. Due to the small number tested, however, differences were not statistically different. It is noteworthy that only one of the SD + TMP patients had to stop therapy because of a rash, whereas therapy was stopped for this reason in three of the SMZ + TMP patients. SD + TMP represents a good alternative to SMZ + TMP in the treatment of urinary tract infections.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 389813     DOI: 10.1007/bf01639020

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  11 in total

1.  Clinical toxicity of sulfonamides.

Authors:  D LEHR
Journal:  Ann N Y Acad Sci       Date:  1957-10-12       Impact factor: 5.691

2.  [A new low-dosage trimethoprim-sulfonamide for long term treatment of chronic urinary tract infections].

Authors:  L Elsborg; F Andreasen; J Scherwin; P Bülow
Journal:  Ugeskr Laeger       Date:  1976-03-15

3.  Kinetics of a sulfadiazine-trimethoprim combination.

Authors:  T Bergan; H Vik-Mo; U Anstad
Journal:  Clin Pharmacol Ther       Date:  1977-08       Impact factor: 6.875

4.  Pharmacokinetic studies with trimethoprim and different doses of sulfadiazine in healthy human subjects.

Authors:  P Männistö; J Tuomisto; N E Saris; T Lehtinen
Journal:  Chemotherapy       Date:  1973       Impact factor: 2.544

5.  A method for the rapid determination of the number of patients to include in a controlled clinical trial.

Authors:  C J Clark; C C Downie
Journal:  Lancet       Date:  1966-12-17       Impact factor: 79.321

6.  Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination.

Authors:  T Bergan; E K Brodwall
Journal:  Acta Med Scand       Date:  1972-12

7.  Bacteriostatic and bactericidal activity of two trimethoprim-sulfonamide combinations.

Authors:  E Böhni
Journal:  Chemotherapy       Date:  1976       Impact factor: 2.544

8.  Antibacterial activity of co-trimazine in vitro and in vivo.

Authors:  B Ekström; H Fellner; U Forsgren; L Magni; B Ortengren
Journal:  Infection       Date:  1979       Impact factor: 3.553

9.  Sulfadiazine-trimethoprim combination in the treatment of urinary tract infections.

Authors:  J Tuomisto; A Kasanen; O V Renkonen
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

10.  Synergistic activity of co-trimazine and co-trimoxazole in the urine.

Authors:  J Acar; B Ekström; H Fellner; U Forsgren; J Guibert; B Huitfeldt; M D Kitzis; L Magni; B Ortengren
Journal:  Infection       Date:  1979       Impact factor: 3.553

View more
  3 in total

1.  Trimethoprim/sulphonamide: concluding remarks.

Authors:  W Marget
Journal:  Infection       Date:  1979       Impact factor: 3.553

Review 2.  Clinical pharmacokinetics of co-trimazine.

Authors:  T Bergan; B Ortengren; D Westerlund
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

Review 3.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.